You are viewing the site in preview mode
Skip to main content
| |
Tofogliflozin treatment group
|
Conventional treatment group
|
Treatment effect (tofogliflozin–conventional treatment) (mean change [95% CI])
|
|---|
|
Right baPWV (cm/s) (mean change; SE)
| |
|
Week 52 (n = 138)
|
1.3 (39.9)
|
77.0 (38.8)
|
− 75.5 (− 171.1, 19.7), p = 0.12
|
|
Week 104 (n = 130)
|
− 67.9 (32.5)
|
34.7 (31.5)
|
− 102.7 (− 182.1, − 23.2), p = 0.012
|
|
Left baPWV (cm/s) (mean change; SE)
| |
|
Week 52 (n = 138)
|
− 7.1 (40.1)
|
76.2 (39.1)
|
− 83.3 (− 179.3, 12.8), p = 0.09
|
|
Week 104 (n = 130)
|
− 33.7 (32.2)
|
67.6 (31.4)
|
− 101.3 (− 180.3, − 22.3), p = 0.012
|
|
Mean baPWV (cm/s) (mean change; SE)
| |
|
Week 52 (n = 138)
|
− 4.2 (39.2)
|
76.9 (38.1)
|
− 81.2 (− 174.9, 12.6), p = 0.09
|
|
Week 104 (n = 130)
|
− 51.9 (31.4)
|
51.2 (30.5)
|
− 103.1 (− 180.1, − 26.2), p = 0.009
|
- Differences in delta change in baPWV from the baseline between the two groups were analyzed using analysis of covariance models that included treatment group, age, sex, use of insulin, baseline mean baPWV, systolic blood pressure, presence of hypertension, and antihypertensive drug administration
